Epidemiology of the plasma-cell disorders

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 4, 2007, Pages 637-664

  Kyle, Robert A ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

agricultural workers; atomic bombs; benzene and solvent exposure; familial aspects; incidence; monoclonal gammopathy of undetermined significance; multiple myeloma; therapeutic and diagnostic radiation

Indexed keywords

BENZENE; COSMETIC; HAIR DYE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; INSECTICIDE; M PROTEIN; PESTICIDE; PETROLEUM;

AGING; AGRICULTURAL WORKER; ALCOHOL CONSUMPTION; AMYLOIDOSIS; BONE METASTASIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; CHROMOSOME DISORDER; CIGARETTE SMOKING; CLINICAL FEATURE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; EXHAUST GAS; FAMILIAL CANCER; FOLLOW UP; GENETIC RISK; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; LABORATORY TEST; MALIGNANT TRANSFORMATION; MEDICAL ASSESSMENT; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; NEGRO; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OCCUPATIONAL DISEASE; OCCUPATIONAL HAZARD; PLASMA CELL; PLASMA CELL DISORDER; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RACE DIFFERENCE; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; WALDENSTROEM MACROGLOBULINEMIA;

AFRICAN AMERICANS; BENZENE DERIVATIVES; CLUSTER ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; PARAPROTEINEMIAS; PLASMA CELLS; RADIATION EFFECTS; RISK FACTORS; UNITED STATES;

EID: 36749099960     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.08.001     Document Type: Review

References (152)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 121 (2003) 749-757
2. Axelsson U., Bachmann R., and Hallen J. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. Acta Medica Scandinavica 179 (1966) 235-247
3. Kyle R.A., Finkelstein S., Elveback L.R., et al. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 40 (1972) 719-724
4. Saleun J.P., Vicariot M., Deroff P., et al. Monoclonal gammopathies in the adult population of Finistere, France. Journal of Clinical Pathology 35 (1982) 63-68
5. Singh J., Dudley Jr. A.W., and Kulig K.A. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. The Journal of Laboratory and Clinical Medicine 116 (1990) 785-789
6. Cohen H.J., Crawford J., Rao M.K., et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. American Journal of Medicine 104 (1998) 439-444 [Erratum in: Am J Med 1998;105: 362]
7. Landgren O., Gridley G., Turesson I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107 (2006 Feb 1) 904-906
8. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine 354 (2006) 1362-1369
9. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clinic Proceedings 79 (2004) 859-866
10. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine 346 (2002) 564-569
11. Surveillance, epidemiology, and end results (SEER) program public-use data (1973-1998) (April 2001), National Cancer Institute, Cancer Statistics Branch, Bethesda (MD)
12. Kyle R.A., Linos A., Beard C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 81 (1992) 1817-1822
13. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings 78 (2003) 21-33
14. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance. British Journal of Haematology 134 (2006) 573-589
15. Rajkumar S.V., Kyle R.A., Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 (2005 Aug 1) 812-817
16. Kyle R.A., and Greipp P.R. Smoldering multiple myeloma. The New England Journal of Medicine 302 (1980) 1347-1349
17. Dimopoulos M.A., Moulopoulos L.A., Maniatis A., et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96 (2000) 2037-2044
18. Dimopoulos M.A., Moulopoulos A., Smith T., et al. Risk of disease progression in asymptomatic multiple myeloma. American Journal of Medicine 94 (1993) 57-61
19. Cesana C., Klersy C., Barbarano L., et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Journal of Clinical Oncology 20 (2002) 1625-1634
20. Weber D.M., Dimopoulos M.A., Moulopoulos L.A., et al. Prognostic features of asymptomatic multiple myeloma. British Journal of Haematology 97 (1997) 810-814
21. Rosinol L., Blade J., Esteve J., et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. British Journal of Haematology 123 (2003) 631-636
22. Witzig T.E., Kyle R.A., O'Fallon W.M., et al. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. British Journal of Haematology 87 (1994) 266-272
23. Polednak A.P. Trends in cancer incidence in Connecticut, 1935-1991. Cancer 74 (1994) 2863-2872
24. Zheng T.Z., Mayne S.T., and Flannery J. The time trends of multiple myeloma in Connecticut, 1935-1987. International Journal of Cancer 50 (1992) 163-164
25. Devesa S.S., Silverman D.T., Young Jr. J.L., et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. Journal of the National Cancer Institute 79 (1987) 701-770
26. Kyle R.A., Nobrega F.T., and Kurland L.T. Multiple myeloma in Olmsted County, Minnesota, 1945-1964. Blood 33 (1969) 739-745
27. Surveillance, epidemiology, and end results (SEER) program (SEER)*Stat database: incidence-SEER 9 Regs Public-Use. November 2002 sub (1973-2000) (2003), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, Bethesda (MD)
28. In: Ries L.A.G., Harkins D., Krapcho M., et al. (Eds). SEER cancer statistics review, 1975-2003 (2006), National Cancer Institute, Bethesda (MD). http://seer.cancer.gov/csr/1975_2003/ based on November 2005 SEER data submission, posted to the SEER Web site [accessed Nov 2005]
29. Linos A., Kyle R.A., O'Fallon W.M., et al. Incidence and secular trend of multiple myeloma in Olmsted County, Minnesota: 1965-77. Journal of the National Cancer Institute 66 (1981) 17-20
30. Kyle R.A., Beard C.M., O'Fallon W.M., et al. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. Journal of Clinical Oncology 12 (1994) 1577-1583
31. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 101 (2004) 2667-2674
32. Clark D.W., and MacMahon B. The incidence of multiple myeloma. Journal of Chronic Diseases 4 (1956) 508-515
33. Modiano M.R., Villar-Werstler P., Crowley J., et al. Evaluation of race as a prognostic factor in multiple myeloma: an ancillary of Southwest Oncology Group Study 8229. Journal of Clinical Oncology 14 (1996) 974-977
34. Wingo P.A., Ries L.A., Rosenberg H.M., et al. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 82 (1998) 1197-1207
35. Lanier A.P., Kelly J.J., Maxwell J., et al. Cancer in Alaska Native people, 1969-2003. Alaska Medicine 48 (2006) 30-59
36. Hernandez J.A., Land K.J., and McKenna R.W. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 75 Suppl (1995) 381-394
37. Riggs J.E. Increasing multiple myeloma mortality rates in the elderly: demonstration of increasing dependency with increasing age upon age group population size. Mechanisms of Ageing and Development 81 (1995) 131-138
38. Hansen N.E., Karle H., and Olsen J.H. Trends in the incidence of multiple myeloma in Denmark 1943-1982: a study of 5500 patients. European Journal of Haematology 42 (1989) 72-76
39. Turesson I., Zettervall O., Cuzick J., et al. Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979. The New England Journal of Medicine 310 (1984) 421-424
40. Levi F., and La Vecchia C. Trends in multiple myeloma. International Journal of Cancer 46 (1990) 755-756
41. Carli P.M., Bailly F., Tavernier C., et al. Multiple myeloma: epidemiological features in a well-defined population in Burgundy, France. International Journal of Epidemiology 18 (1989) 330-333
42. Phekoo K.J., Schey S.A., Richards M.A., et al. Consultant Haematologists, South Thames Haematology Specialist Committee. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. British Journal of Haematology 127 (2004) 299-304
43. National Office of Vital Statistics. Vital statistics of the United States, 1949. Part I. Natality, mortality, marriage, divorce, morbidity, and life table data for the United States: general tables by place of occurrence with supplemental tables for Hawaii, Puerto Rico, Virgin Islands, and Alaska (1951), United States Government Printing Office, Washington (DC)
44. National Center for Health Statistics. Vital statistics of the United States, 1974. Vol 2. Mortality (Part A). ([PHS]79-1101.) (1978), U.S. Department of Health, Education, and Welfare, Public Health Service, Hyattsville, (MD)
45. National Center for Health Statistics. Vital statistics of the United States, 1988. Vol 2. Mortality (Part A) (1991), U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Hyattsville (MD)
46. Stober J., and Asal N.R. Multiple myeloma in Oklahoma: racial, age, sex, geographic and time variations. Southern Medical Journal 69 (1976) 298-302
47. Greenwald P. Cancer incidence and mortality in New York State (exclusive of New York City) (1976), New York State Department of Health, Bureau of Cancer Control, Albany (NY)
48. Miller B., Ries L.A., Hankey B.F., et al. Surveillance, Epidemiology, and End Results (SEER) cancer statistics review: program public-use data CD Rom (1973-1990) (1993), National Cancer Institute, Bethesda (MD) NIH Publication No. 93-2789
49. Davis D.L., Hoel D., Fox J., et al. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet 336 (1990) 474-481
50. Davis D.L., Hoel D., Fox J., et al. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the United States. Annals of the New York Academy of Sciences 609 (1990) 5-48
51. Schwartz J. Multinational trends in multiple myeloma. Annals of the New York Academy of Sciences 609 (1990) 215-224
52. Cuzick J. International time trends for multiple myeloma. Annals of the New York Academy of Sciences 609 (1990) 205-214
53. Ichimaru M., Ishimaru T., Mikami M., et al. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: relationship to radiation dose absorbed by marrow. Journal of the National Cancer Institute 69 (1982) 323-328
54. Shimizu Y., Schull W.J., and Kato H. Cancer risk among atomic bomb survivors. The RERF Life Span Study. Radiation Effects Research Foundation. The Journal of the American Medical Association 264 (1990) 601-604
55. Preston D.L., Kusumi S., Tomonaga M., et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiation Research 137 Suppl (1994) S68-S97 [Erratum in: Radiat Res 1994;139: 129]
56. Neriishi K., Yoshimoto Y., Carter R.L., et al. Monoclonal gammopathy in atomic bomb survivors. Radiation Research 133 (1993) 351-359
57. Tsukasaki K., Iwanaga M., and Tomonaga M. Late hematological effects in the atomic bomb survivors. International Congress Series 1299 (2007) 67-72
58. Cuzick J. Radiation-induced myelomatosis. The New England Journal of Medicine 304 (1981) 204-210
59. Lewis E.B. Leukemia, multiple myeloma, and aplastic anemia in American radiologists. Science 142 (1963) 1492-1494
60. Matanoski G.M., Seltser R., Sartwell P.E., et al. The current mortality rates of radiologists and other physician specialists: specific causes of death. American Journal of Epidemiology 101 (1975) 199-210
61. Sigurdson A.J., Doody M.M., Rao R.S., et al. Cancer incidence in the US radiologic technologists health study, 1983-1998. Cancer 97 (2003) 3080-3089
62. Boice Jr. J.D., Morin M.M., Glass A.G., et al. Diagnostic x-ray procedures and risk of leukemia, lymphoma, and multiple myeloma. The Journal of the American Medical Association 265 (1991) 1290-1294 [Erratum in: JAMA 1991;265: 2810]
63. Hatcher J.L., Baris D., Olshan A.F., et al. Diagnostic radiation and the risk of multiple myeloma (United States). Cancer Causes & Control 12 (2001) 755-761
64. Schroeder J.C., and Savitz D.A. Lymphoma and multiple myeloma mortality in relation to magnetic field exposure among electric utility workers. American Journal of Industrial Medicine 32 (1997) 392-402
65. Darby S.C., Kendall G.M., Fell T.P., et al. A summary of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes. British Medical Journal (Clinical Research Ed.) 296 (1988) 332-338
66. Muirhead C.R., Bingham D., Haylock R.G., et al. Follow up of mortality and incidence of cancer 1952-98 in men from the UK who participated in the UK's atmospheric nuclear weapon tests and experimental programmes. Occupational and Environmental Medicine 60 (2003) 165-172
67. Gilbert E.S., Petersen G.R., and Buchanan J.A. Mortality or workers at the Hanford site: 1945-1981. Health Physics 56 (1989) 11-25
68. Wing S., Richardson D., Wolf S., et al. A case control study of multiple myeloma at four nuclear facilities. Annals of Epidemiology 10 (2000) 144-153
69. Lopez-Abente G., Aragones N., Pollan M., et al. Leukemia, lymphomas, and myeloma mortality in the vicinity of nuclear power plants and nuclear fuel facilities in Spain. Cancer Epidemiology, Biomarkers & Prevention 8 (1999) 925-934
70. Carpenter L.M., Higgins C.D., Douglas A.J., et al. Cancer mortality in relation to monitoring for radionuclide exposure in three UK nuclear industry workforces. British Journal of Cancer 78 (1998) 1224-1232
71. Smith P.G., and Douglas A.J. Mortality of workers at the Sellafield plant of British Nuclear Fuels. British Medical Journal (Clinical Research Ed.) 293 (1986) 845-854
72. Omar R.Z., Barber J.A., and Smith P.G. Cancer mortality and morbidity among plutonium workers at the Sellafield plant of British Nuclear Fuels. British Journal of Cancer 79 (1999) 1288-1301 [Erratum in: Br J Cancer 1999;79: 1946]
73. Forman D., Cook-Mazaffari P., Darby S., et al. Cancer near nuclear installations. Nature 329 (1987) 499-505
74. Khuder S.A., and Mutgi A.B. Meta-analyses of multiple myeloma and farming. American Journal of Industrial Medicine 32 (1997) 510-516
75. Milham Jr. S. Leukemia and multiple myeloma in farmers. American Journal of Epidemiology 94 (1971) 507-510
76. Burmesiter L.F. Cancer mortality in Iowa farmers, 1971-78. Journal of the National Cancer Institute 66 (1981) 461-464
77. Brown L.M., Brumeister L.F., Everett G.D., et al. Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes & Control 4 (1993) 153-156
78. Cantor K.P., and Silberman W. Mortality among aerial pesticide applicators and flight instructors: follow-up from 1965-1988. American Journal of Industrial Medicine 36 (1999) 239-247
79. Baris D., Silverman D.T., Brown L.M., et al. Occupation, pesticide exposure and risk of multiple myeloma. Scandinavian Journal of Work Environment & Health 30 (2004) 215-222
80. Semenciw R.M., Morrison H.I., Riedel D., et al. Multiple myeloma mortality and agricultural practices in the Prairie provinces of Canada. Journal of Occupational Medicine 35 (1993) 557-561
81. Wiklund K., and Holm L.E. Trends in cancer risks among Swedish agricultural workers. Journal of the National Cancer Institute 77 (1986) 657-664
82. Eriksson M., and Karlsson M. Occupational and other environmental factors and multiple myeloma: a population based case-control study. British Journal of Industrial Medicine 49 (1992) 95-103
83. Heineman E.F., Olsen J.H., Pottern L.M., et al. Occupational risk factors for multiple myeloma among Danish men. Cancer Causes & Control 3 (1992) 555-568
84. Pottern L.M., Heineman E.F., Olsen J.H., et al. Multiple myeloma among Danish women: employment history and workplace exposures. Cancer Causes & Control 3 (1992) 427-432
85. Kristensen P., Andersen A., Irgens L.M., et al. Incidence and risk factors of cancer among men and women in Norwegian agriculture. Scandinavian Journal of Work Environment & Health 22 (1996) 14-26
86. Nanni O., Falcini F., Buiatti E., et al. Multiple myeloma and work in agriculture: results of a case-control study in Forli, Italy. Cancer Causes & Control 9 (1998) 277-283
87. Viel J.F., and Richardson S.T. Lymphoma, multiple myeloma and leukaemia among French farmers in relation to pesticide exposure. Social Science & Medicine 37 (1993) 771-777
88. Pearce N.E., Smith A.H., and Fisher D.O. Malignant lymphoma and multiple myeloma linked with agricultural occupations in a New Zealand Cancer Registry-based study. American Journal of Epidemiology 121 (1985) 225-237
89. Guidotti S., Wright W.E., and Peters J.M. Multiple myeloma in cosmetologists. American Journal of Industrial Medicine 3 (1982) 169-171
90. Spinelli J.J., Gallagher R.P., Band P.R., et al. Multiple myeloma, leukemia, and cancer of the ovary in cosmetologists and hairdressers. American Journal of Industrial Medicine 6 (1984) 97-102
91. Brown L.M., Everett G.D., Burmeister L.F., et al. Hair dye use and multiple myeloma in white men. American Journal of Public Health 82 (1992) 1673-1674
92. Zahm S.H., Weisenburger D.D., Babbitt P.A., et al. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. American Journal of Public Health 82 (1992) 990-997
93. Herrinton L.J., Weiss N.S., Koepsell T.D., et al. Exposure to hair-coloring products and the risk of multiple myeloma. American Journal of Public Health 84 (1994) 1142-1144
94. Altekruse S.F., Henley S.J., and Thun M.J. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United States). Cancer Causes & Control 10 (1999) 617-625
95. La Vecchia C., and Tavani A. Epidemiological evidence on hair dyes and the risk of cancer in humans. European Journal of Cancer Prevention 4 (1995) 31-43
96. Aksoy M., Erdem S., Dincol G., et al. Clinical observations showing the role of some factors in the etiology of multiple myeloma: a study in 7 patients. Acta Haematologica 71 (1984) 116-120
97. Aksoy M., Dincol K., Erdem S., et al. Details of blood changes in 32 patients with pancytopenia associated with long-term exposure to benzene. British Journal of Industrial Medicine 29 (1972) 56-64
98. Goldstein B.D. Is exposure to benzene a cause of human multiple myeloma?. Annals of the New York Academy of Sciences 609 (1990) 225-230
99. Wong O. Risk of acute myeloid leukaemia and multiple myeloma in workers exposed to benzene. Occupational and Environmental Medicine 52 (1995) 380-384
100. Wong O., and Raabe G.K. Multiple myeloma and benzene exposure in a multinational cohort of more than 250,000 petroleum workers. Regulatory Toxicology and Pharmacology 26 (1997) 188-199
101. Sonoda T., Nagata Y., Mori M., et al. Meta-analysis of multiple myeloma and benzene exposure. Journal of Epidemiology 11 (2001) 249-254
102. Bergsagel D.E., Wong O., Bergsagel P.L., et al. Benzene and multiple myeloma: appraisal of the scientific evidence. Blood 94 (1999) 1174-1182
103. Divine B.J., Hartman C.M., and Wendt J.K. Update of the Texaco mortality study 1947-93: Part II. Analyses of specific causes of death for white men employed in refining, research, and petrochemicals. Occupational and Environmental Medicine 56 (1999) 174-180
104. Infante P.F. Benzene exposure and multiple myeloma: a detailed meta-analysis of benzene cohort studies. Annals of the New York Academy of Sciences 1076 (2006) 90-109
105. Flodin U., Fredriksson M., and Persson B. Multiple myeloma and engine exhausts, fresh wood, and creosote: a case-referent study. American Journal of Industrial Medicine 12 (1987) 519-529
106. Bezabeh S., Engel A., Morris C.B., et al. Does benzene cause multiple myeloma? An analysis of the published case-control literature. Environmental Health Perspectives 104 Suppl. 6 (1996) 1393-1398
107. Lee W.J., Baris D., Jarvholm B., et al. Multiple myeloma and diesel and other occupational exposures in Swedish construction workers. International Journal of Cancer 107 (2003) 134-138
108. Wong O. Is there a causal relationship between exposure to diesel exhaust and multiple myeloma?. Toxicological Reviews 22 (2003) 91-102
109. Tollerud D.J., Brinton L.A., Stone B.J., et al. Mortality from multiple myeloma among North Carolina furniture workers. Journal of the National Cancer Institute 74 (1985) 799-801
110. Demers P.A., Boffetta P., Kogevinas M., et al. Pooled reanalysis of cancer mortality among five cohorts of workers in wood-related industries. Scandinavian Journal of Work Environment & Health 21 (1995) 179-190
111. Kolstad H.A., Lynge E., and Olsen J. Cancer incidence in the Danish reinforced plastics industry. IARC Scientific Publications 127 (1993) 301-308
112. Lundberg I., and Milatou-Smith R. Mortality and cancer incidence among Swedish pain industry workers with long-term exposure to organic solvents. Scandinavian Journal of Work Environment & Health 24 (1998) 270-275
113. Demers P.A., Vaughan T.L., Koepsell T.D., et al. A case-control study of multiple myeloma and occupation. American Journal of Industrial Medicine 23 (1993) 629-639
114. Heineman E.F., Zahm S.H., McLaughlin J.K., et al. A prospective study of tobacco use and multiple myeloma: evidence against an association. Cancer Causes & Control 3 (1992) 31-36
115. Brown L.M., Everett G.D., Gibson R., et al. Smoking and risk of non-Hodgkin's lymphoma and multiple myeloma. Cancer Causes & Control 3 (1992) 49-55
116. Adami J., Nyren O., Bergstrom R., et al. Smoking and the risk of leukemia, lymphoma, and multiple myeloma (Sweden). Cancer Causes & Control 9 (1998) 49-56
117. Brown L.M., Pottern L.M., Silverman D.T., et al. Multiple myeloma among blacks and whites in the United States: role of cigarettes and alcoholic beverages. Cancer Causes & Control 8 (1997) 610-614
118. Linet M.S., McLaughlin J.K., Hsing A.W., et al. Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study. Leukemia Research 16 (1992) 621-624
119. Mills P.K., Newell G.R., Beeson W.L., et al. History of cigarette smoking and risk of leukemia and myeloma: results from the Adventist health study. Journal of the National Cancer Institute 82 (1990) 1832-1836
120. Friedman G.D., and Herrinton L.J. Obesity and multiple myeloma. Cancer Causes & Control 5 (1994) 479-483
121. Brown L.M., Gridley G., Pottern L.M., et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes & Control 12 (2001) 117-125
122. Blair C.K., Cerhan J.R., Folsom A.R., et al. Anthropometric characteristics and risk of multiple myeloma. Epidemiology 16 (2005) 691-694
123. Fritschi L., Ambrosini G.L., Kliewer E.V., et al., Canadian Cancer Registries Epidemiologic Research Group. Dietary fish intake and risk of leukaemia, multiple myeloma, and non-Hodgkin lymphoma. Cancer Epidemiology, Biomarkers & Prevention 13 (2004) 532-537
124. Brown L.M., Gibson R., Burmeister L.F., et al. Alcohol consumption and risk of leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Leukemia Research 16 (1992) 979-984
125. Kagan E., Jacobson R.J., Yeung K.Y., et al. Asbestos-associated neoplasms of B cell lineage. American Journal of Medicine 67 (1979) 325-330
126. Schwartz D.A., Vaughan T.L., Heyer N.J., et al. B cell neoplasms and occupational asbestos exposure. American Journal of Industrial Medicine 14 (1988) 661-671
127. Hussein M.A., George R., Rybicki L., et al. Skeletal trauma preceding the development of plasma cell dyscrasia: eight case reports and review of the literature. Medical Oncology 20 (2003) 349-354
128. Mongkonsritragoon W., Kyle R.A., Shreck R.R., et al. Primary plasmacytoma at the site of exit wounds after electrical injury. American Journal of Hematology 58 (1998) 77-79
129. Riggs J.E. Increasing multiple myeloma mortality among the elderly: a manifestation of aging and differential survival. Mechanisms of Ageing and Development 77 (1995) 227-234
130. Johnston J.M., Grufferman S., Bourguet C.C., et al. Socioeconomic status and risk of multiple myeloma. Journal of Epidemiology and Community Health 39 (1985) 175-178
131. Cella D.F., Orav E.J., Kornblith A.B., et al. Socioeconomic status and cancer survival. Journal of Clinical Oncology 9 (1991) 1500-1509
132. Baris D., Brown L.M., Silverman D.T., et al. Socioeconomic status and multiple myeloma among US blacks and whites. American Journal of Public Health 90 (2000) 1277-1281
133. Lenhard Jr. R.E., Enterline J.P., Crowley J., et al. The effects of distance from primary treatment centers on survival among patients with multiple myeloma. Journal of Clinical Oncology 5 (1987) 1640-1645
134. Cohen H.J., Bernstein R.J., and Grufferman S. Role of immune stimulation in the etiology of multiple myeloma: a case control study. American Journal of Hematology 24 (1987) 119-126
135. Linet M.S., Harlow S.D., and McLaughlin J.K. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Research 47 (1987) 2978-2981
136. Herrinton L.J., Demers P.A., Koepsell T.D., et al. Epidemiology of the M-component immunoglobulin types of multiple myeloma. Cancer Causes & Control 4 (1993) 83-92
137. Soderberg K.C., Hagmar L., Schwartzbaum J., et al. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 4 (2004) 51
138. Koepsell T.D., Daling J.R., Weiss N.S., et al. Antigenic stimulation and the occurrence of multiple myeloma. American Journal of Epidemiology 126 (1987) 1051-1062
139. Lewis D.R., Pottern L.M., Brown L.M., et al. Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes & Control 5 (1994) 529-539
140. Kyle R.A., Herber L., Evatt B.L., et al. Multiple myeloma: a community cluster. The Journal of the American Medical Association 213 (1970) 1339-1341
141. Ende M. Multiple myeloma: a cluster in Virginia?. Virginia Medical 106 (1979) 115-116
142. Kyle R.A., and Greipp P.R. Multiple myeloma: houses and spouses. Cancer 51 (1983) 735-739
143. Maldonado J.E., and Kyle R.A. Familial myeloma: report of eight families and a study of serum proteins in their relatives. American Journal of Medicine 57 (1974) 875-884
144. Bizzaro N., and Pasini P. Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings. Haematologica 75 (1990) 58-63
145. Shoenfeld Y., Berliner S., Shaklai M., et al. Familial multiple myeloma: a review of thirty-seven families. Postgraduate Medical Journal 48 (1982) 12-16
146. Grosbois B., Jego P., Attal M., et al. Familial multiple myeloma: report of fifteen families. British Journal of Haematology 105 (1999) 758-770
147. Lynch H.T., Sanger W.G., Pirruccello S., et al. Familial multiple myeloma: a family study and review of the literature. Journal of the National Cancer Institute 93 (2001) 1479-1483
148. Lynch H.T., Watson P., Tarantolo S., et al. Phenotypic heterogeneity in multiple myeloma famillies. Journal of Clinical Oncology 23 (2005) 685-693
149. Deshpande H.A., Hu X.P., Marino P., et al. Anticipation in familial plasma cell dyscrasias. British Journal of Haematology 103 (1998) 696-703
150. Brown L.M., Linet M.S., Greenberg R.S., et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 85 (1999) 2385-2390
151. Segel G.B., and Lichtman M.A. Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Molecules and Diseases 32 (2004) 246-261
152. Snowden J.A., and Greaves M. IgA lambda myeloma presenting concurrently in identical twins with subsequent transformation to 'aggressive phase' in one. Clinical and Laboratory Haematology 17 (1995) 95-96